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ABSTRACT
Extracellular vesicles have been described in non-paracrine cellular interactions in cancer. We report a
similar phenomenon in B-cell precursor (BCP) acute lymphoblastic leukaemia (ALL). Using advanced
microscopy and high throughput screening, we further characterise a subset of large vesicles (LEVs)
identified in cell lines, murine models of human BCP-ALL and clinical samples. Primary ALL blasts and
cell lines released heterogeneous anucleate vesicles <6 micron into extracellular fluids. Larger LEVs
were enclosed in continuous membranes, contained intact organelles and demonstrated an orga-
nised cytoskeleton. An excess of circulating CD19-positive LEVs were observed in diagnostic samples
and isolated from mice engrafted with BCP-ALL primary cells. LEVs exhibited dynamic shape change
in vitro and were internalised by other leukaemic cell lines leading to phenotypic transformation
analogous to the cell of origin. In patient-derived xenografts, LEVs were released by primary ALL cells
into extracellular spaces and internalised bymurinemesenchymal cells in vivo. Collectively these data
highlight the heterogeneity but accessibility of LEVs in clinical samples and their potential to provide
a unique insight into the biology of the cell of origin and to their development as novel biomarkers to
aid diagnosis and improve therapeutic outcomes.
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Along with direct contact and soluble factors, intercel-
lular interactions through extracellular vesicles are
increasingly recognised as modes of local as well distal
intercellular communication. Vesicles show consider-
able heterogeneity of size and cargo and are classified
into three types based on their biogenesis.[1] Exosomes
(30–150 nm) are derived from intraluminal multivesi-
cular bodies of endosomal origin and released by exo-
cytosis; extracellular vesicles (EVs) are budded from
the plasma membrane and generally 100–1000 nm in
size;[2] apoptotic bodies (AB) are formed by cells
undergoing apoptosis and are reported to be >1 µm
in size.[3,4] Larger EVs or oncosomes [5] (<10 µm)
have also been reported to be a product of non-apop-
totic cell membrane blebbing in prostate cancer cell
lines.[6] We recently reported that EVs are released
by B-cell precursor (BCP) acute lymphoblastic leukae-
mia (ALL) cells in vitro and in vivo.[7] Mechanistically,
internalisation of leukaemic EVs (LEVs) by stromal
cells resulted in a metabolic shift from oxidative
phosphorylation to aerobic glycolysis, potentially facil-
itating leukaemic cell survival.
Applying comprehensive advanced imaging techni-
ques, to enable visual assessment and high-throughput
quantification of size and parent cell marker expres-
sion, we have further characterised LEVs using cell
lines, patient derived xenograft (PDX) models and
samples obtained from patients with ALL.
Patients and methods
Cells and cell lines
Bone marrow samples were obtained from children
with ALL on treatment after consent, fractionated
into plasma and mononuclear fractions and stored.
Human bone marrow endothelial cells (BMEC) or
mesenchymal stem cells (hMSCs) were derived from
bone marrow biopsies as previously described.[8] See
Supplemental Table S1 for cell lines used. BCP-ALL
cell lines were lentivirally or retrovirally engineered to
express fluorescent proteins. The studies were
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approved by Tameside and Glossop (Manchester, UK;
Reference 07/Q1402/56) research ethics committee.
Vesicle isolation from cell lines
ALL cells were washed with PBS and seeded in serum
free RPMI at a density of 3.3 × 106–1 × 107 cells ml–1
for 24 h prior to isolation of LEVs to eliminate bovine
vesicle contamination. Cell viability was checked using
trypan blue exclusion assay and only cultures with
>97% viability were used. Isolation of large EVs was
optimised to ensure protection of the intact membrane
and preservation of morphology and phenotype.
Depending on the downstream experiment, vesicles
were isolated by a combination of filtration and differ-
ential centrifugation as follows: cells were centrifuged
twice at 200 × g for 5 min followed by filtration using a
double layered, sterile 5 µm pore cell sieve (BioDesign,
New York, NY, USA) (Figure S3). Supernatant was
centrifuged at 2000 × g 20 minutes, and the super-
natant collected for sequential centrifugation at 10,000
× g for 30 minutes followed by 100,000 × g for 2 h to
collect exosomes. Downstream methods for analysing
large LEVs which were found in the 2000 × g fraction
were optimised to enable further exclusion of cell deb-
ris by visual inspection and stringent gating strategies
(see supplemental methods). Human ALL cells and
LEVs were retrieved from the spleens of mice using
anti-human CD19 immunocapture and visualised by
transmission electron microscopy (TEM).
Imaging flow cytometry analysis of LEVs in clinical
samples
The BCP-ALL cell line NALM-6 expresses the B cell
marker CD19 and was used to explore parent cell
marker expression on LEVs. LEVs were isolated as
described and analysed for CD19 expression using the
imaging flow cytometer (Mark II Image Stream,
Amnis, Seattle, WA, USA). Data were acquired from
channels 1 (bright field), 2 (488 nm), 3 (651 nm) and
12 (785 nm side scatter). Specific gating strategies
applied to the imaging flow cytometry acquisitions
disregarded cell debris from further analysis (see
Supplemental Figure 1(b)). Objects were designated
vesicles using the following gating strategy: speed
beads removed, diameter mask applied using the bright
field image in channel 1, size <6 µm, aspect ratio of
>0.4 (to exclude debris) and only focused events were
considered. Using INSPIRE software (INSPIRE version
200.1.388.0., Amnis, USA) 10,000 events were acquired
and the data merged and analysed using IDEAS soft-
ware (Amnis). NALM-6 vesicles were spiked into
healthy plasma to establish compensation matrices for
dual labelled imaging flow cytometry on clinical sam-
ples. Anti-human CD19 PE_Cy7 and anti-human
CD61 FITC antibodies were used to detect human
CD19+ LEVs and platelets respectively. The analysis
template was applied to vesicles detected in patient
plasma where 5 × 200,000 events were acquired using
× 60 magnification and extended depth of field.
Detection of LEVs in ALL patient plasma
During initial fractionation of the bone marrow aspi-
rate, an amended protocol was used to maximise sub-
sequent LEV retrieval from bone marrow plasma
including slower speed centrifugation at 200 × g
10 min. To ensure acquisition of the maximum num-
ber of events using imaging flow cytometry, patient-
derived plasma was used undiluted during the labelling
protocol. To eliminate non-specific binding, plasma
samples were treated with Human Fc block (BD
Biosciences Cat: 564219, San Jose, CA) for 5 min
prior to the addition of anti-human CD19 PE_CY7
(Clone H1B19, Biolegend Cat: 302216) and anti-
human CD61 FITC (Clone VI-PL2, Biolegend Cat:
336404) antibodies, which had been purified by affinity
chromatography to remove unlabelled antibody and
unconjugated label, to eliminate non-specific binding.
The entire plasma fraction was analysed by imaging
flow cytometry using the stringent gating strategies
described.
Chemicals, reagents and antibodies
See Supplemental Methods and Table S2.
Immunofluorescence microscopy
Viable cultures containing ALL cells and LEVs were
immobilised onto CellTak coated glass coverslips, fixed
with 3.7% paraformaldehyde probed using antibodies
as detailed and imaged as described. LAMP1 and Talin:
Super resolution microscopy was performed using a
gSTED (gated Stimulated Emission Depleted) Leica
TCS SP8 confocal microscope (Leica Biosystems,
Wetzler, Germany) equipped with x63, NA1.4 oil
lens, PMT and Hybrid (HyD) detectors, and with
white laser (470–670 nm) and 405 UV laser. The soft-
ware used was LAS X (Leica). Vinculin and time lapse
images were captured using a Zeiss Axiovert 200 M
microscope (Call Zeiss AG, Jena, Germany) fitted with
a Zeiss_Plan-Fluor 0.5 numerical aperture connected to
an Andor iXon DU888+ (Andor, Belfast, Northern
Ireland) low light black and white camera.
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Illumination by UV light source was filtered using the
SEDAT wheel filter set with appropriate wavelengths.
The imaging system and image composites were
achieved using Metamorph software (Molecular
Devices, Sunnyvale, CA, USA).
Transmission electron microscopy (TEM)
Images were captured using a Biotwin Philips TECNAI
G2 transmission electron microscope (FEI Tecnai G2
T12 Biotwin microscope, Hillsboro, Oregon, US).
Time-lapse microscopy
BMECs (dsRED) and GFP expressing SD1 cells were co-
cultured in fibronectin-coated glass bottomed plates
(IWAKI, Shizuoka, Japan). Images were captured at 5-
min intervals using bright field and UV sourced light
filtered by the appropriate SEDAT filter using
Metamorph software and videos created using ImageJ
(MacBiophotonics [9]).
Vesicle uptake
LEVs isolated from serum-free 24-h SD1 cell cultures
(2000 × g fraction) were labelled with Dio C 18
lipophilic tracer (Life Technologies, Carlsbad, CA,
USA; Cat: D275) at a concentration of 1 µg ml–1
for 30 min at 37°C. Labelled LEVs were washed for
10 min with inversion using 4 × volume of PBS and
centrifuged at 2000 × g 20 min. The pellet was
resuspended in 500 µl serum-free RPMI and added
to ALL cell lines SupB15, REH or TOM1 cells, or the
normal lymphoblastoid cell line HRC57, seeded onto
fibronectin coated glass bottomed plates and incu-
bated at 37°C for 24 h. Cells were washed with PBS,
fixed with 3.7% paraformaldehyde and counter-
stained with either Cell Mask orange or Alexa-fluor
555 phalloidin and mounted using Prolong DAPI
mountant and imaged as described.
Imaging-flow cytometry analysis of SD1 cells
AEP activity binding probe was analysed with an ima-
ging flow cytometer (Image stream, Amnis).
Patient derived human leukaemia xenograft
All animal procedures were approved by the Cancer
Research UK, Manchester Institute’s Animal Welfare
and Ethical Review Body (AWERB) and performed
under a Project License issued by the UK Home
Office, in keeping with the Home Office Animal
Scientific Procedures Act, 1986. Six- to 12-week-old
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were
transplanted intrafemorally or intravenously with
1 × 106 ALL cell lines lentiviral transduced to express
luciferase and GFP (NALM6) or mCherry (SupB15).
Bone marrow was flushed with PBS and resulting cells
seeded in vitro onto fibronectin-coated glass bottomed
plates for fluorescence microscopy.
Results
BCP-ALL cells produce extracellular vesicles which
are quantifiable in clinical samples
When grown under optimal conditions (>97% cell
viability) ALL and lymphoblastoid cell lines released
sub-cellular vesicles in cell culture media visible using
light microscopy (Supplemental Figure 1(a)).
Previously using fluorescence microscopy of cytospin
preparations, we identified LAMP1 positive discrete
vesicular compartments localised to the periphery of
the BCP-ALL cell line SD1.[10] Using a highly specific
asparagine endopeptidase (AEP) activity binding probe
(ABP),[11] we demonstrated that the compartment
contained the active form of the lysosomal cysteine
protease AEP. The AEP-ABP was used here to visualise
SD1 cells and EVs in suspension, using imaging flow
cytometry. Vesicles ranging from 2.5–5 µm distinct
from but tethered to SD1 parent cells were identified
(Figure 1(a)) along with EVs in suspension (Figure 1
(b)); a proportion of which were positive for the active
form of the AEP indicated by red fluorescence. We
recently reported that BCP-ALL cells produce LEVs
expressing the B cell surface marker CD19.[7] Using
the gating strategy described we found that whilst
97.9% NALM6 cells (BCP-ALL cell line) were positive
for CD19 by imaging flow cytometry, only ~35% of the
LEVs produced over 24 h expressed this membrane
marker (Figure 1(c)).
Heterogeneity in vesicle size led us to investigate
the possibility of LEV aggregation. Imaging flow
cytometry (Image Stream X Mark II, Amnis) allowed
both quantification and visualisation of each event
that passed through the flow cell.[12] NALM6 LEVs
were spiked into normal human plasma to enable
optimisation of a sensitive screening method. CD19
PE_Cy7 (magenta) and CD61 FITC (green) were
used to distinguish between LEVs and platelet
derived microparticles that express CD61 (Figure 1
(d)). This method established a compensation matrix
and gating strategy (Supplemental Figure 1(b)) used
to interrogate bone marrow plasma taken at diagno-
sis from three ALL patients. The smallest vesicle
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detected with confidence using this method was
362 nm. Figure 1(e) demonstrates that CD19+
LEVs (upper left) and CD61+ microparticles (upper
right) span a similar size range of up 5.9 µm. The
size distribution for CD61+ population was compar-
able across all three patient samples with a median of
1.6, 1.68 and 1.76 µm respectively (upper right). By
contrast, the size range of CD19+ LEVs was more
heterogeneous with a median of 2.02, 1.84 and
2.84 µm respectively (upper left). The lower panel
shows the frequency of CD19+ (magenta) and CD61
+ (green) events detected concurrently using dual
labelling. Any events where dual positive labelling
was detected were visually inspected and found to
be as a result of platelet adherence to an LEV
(Supplemental Figure 1(c)). Imaging flow cytometry
provided quantification of LEV number, analysis of
size distribution and identity of cell of origin. As
reported previously in a normal donor population,
[12] distinction from similar-size particles in clinical
samples was achieved without the need for filtra-
tion.[13]
Transmission electron microscopy (TEM) reveals
heterogeneity of LEVs
Different techniques for vesicle isolation for subsequent





















































































Figure 1. LEVs are detected by imaging flow cytometry and distinguishable from platelets in clinical samples. (a) LEVs tethered to
the parent SD1 cell were observed using imaging flow cytometry. SD1 cells cultured in serum-free RPMI for 24 h were incubated
with an AEP activity binding-probe which fluoresces red on cleavage by active AEP a lysosomal cysteine protease. Fluorescence and
brightfield images were acquired enabling visualisation of red fluorescence from cleaved ABP (emission 555 nm) localised to the
extracellular vesicle. Scale bar is 10 µm. (b) LEVs of varying sizes (2–5.5 µm) were also observed in suspension in healthy SD1
cultures (>97% viability). Cells were probed with an AEP activity-binding probe as before. (c) NALM6 LEVs express the BCP marker
CD19. CD19 expression was detected by imaging flow cytometry (Amnis Imagestream) in cells (left panel) and a proportion of LEVs
(right panel) released into serum free RPMI over 24 h. FCS files were used to compare expression levels in the two populations using
FlowJo. Plots showed more uniform LEV CD19+ mean fluorescence intensity (yellow) in the parent cells (97.9%) compared with LEVs
(35%). Unstained (red) and isotype control (blue) are also shown. (d) Imaging flow cytometry distinguished NALM6 LEVs from
platelets. LEVs were spiked into normal human plasma. CD61 was used to distinguish platelets from CD19 positive LEVs. Examples
of the brightfield images captured at × 60 magnification with an extended depth of field, diameter mask applied for quantification
and FITC and PE_Cy7 channels are shown. Scale bar represents 7 µm. A compensation matrix for dual labelling was created from
these data for subsequent experiments. (e) CD19+ LEVs are present in bone marrow plasma from three BCP-ALL patients at
diagnosis. Imaging flow cytometry identified CD19 PE_Cy7 (magenta) and CD61 FITC (green) positive vesicles in dual labelled bone
marrow plasma samples. Dual labelling enabled distinction between LEVs and platelets in clinical samples. (Upper panel) Box-plot
representation of size of vesicles detected. Box for each category represents the interquartile range of values with whiskers at 1 and
99 percentiles. Horizontal line and plus symbol denote median and mean respectively; outlier values are represented by stacked
dots. Although a similar size range was detected, LEV (CD19+) size distribution was more heterogeneous compared with that of EVs
which were present in the same sample and positive for the platelet marker CD61 (upper panel). (Lower panel) Histograms show
the normalised frequency of diameter (µm) for comparison.
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were explored.[2] There were considerable variations in
quality, preservation and content of vesicles prepared
using these different methods. TEM performed on
fixed pellets derived from sequential centrifugation and
ultracentrifugation of SD1 cell culture media revealed
heterogeneous, membrane-bound vesicles ranging from
50 nm to 5.7 µm in size (Supplemental Figure 2(a)).
Similar subcellular vesicles were identified from REH
and HRC57 cell lines (Supplemental Figure 2(b)).
However, this method resulted in distortion and rupture
of larger vesicles, leading to difficulties distinguishing
between intercellular/vesicular contents and bone fide
vesicles. To avoid this, cell culture supernatants from
healthy SD1 cultures were filtered through double
layered 5 µm pore cell sieves after low speed centrifuga-
tion, seeded onto flexible ACLAR film pre-coated with
CellTak, and processed for TEM by transverse section-
ing. Vesicles of different sizes, adherent to the substrate
were identified. Intact cellular organelles including mito-
chondria, lysosomes, Golgi and intermediate filaments,
but no nucleus/chromatin condensation products were
identified within the outer membrane of the large vesi-
cles (Figure 2(a), 2(b)).
To demonstrate that these LEVs were not solely an
in vitro phenomenon, CD19+ primary ALL cells were
engrafted into NSG mice following intrafemoral injec-
tion. Nineteen days later, xenografted mice were
culled and LEVs isolated from harvested spleens by
immunocapture using a human CD19 antibody.
Eluted cells and LEVs were plated onto CellTak-
coated ACLAR film and processed for TEM. Both
cells and LEVs adhered to substrate. Transverse sec-
tions revealed the clear presence of a nucleus in the
parent ALL cell, whilst mitochondria were identified
in both the cell and LEV (Figure 2(c)). Serial sections
demonstrated that the LEV was 4.6 × 4 × 5.7 µm in
size taking into account major membrane protrusions,
with an intact membrane and mitochondria but
anucleate (Figure 2(d)). These LEVs displayed an
intact but irregular outer membrane with cytoplasmic
protrusions analogous to the parent cells when














Figure 2. Cell line and primary ALL cell derived LEVs contain intact organelles. (a, b) Transmission electron microscopy (TEM) of cell-
depleted, viable SD1 cell culture supernatant, revealed large vesicles. Serum free supernatants from 24-h cultures of SD1 cells were cell
depleted by centrifugation (300 × g, twice) and filtered through a double layered, sterile 5 µm pore micro sieve. Low speed
centrifugation (2000 × g) of the filtrate provided a population of larger vesicles which were immobilised onto CellTak coated ACLAR
film. Samples were processed for TEM by fixation in glutaraldehyde and then incubated with osmium tetroxide and uranyl acetate.
Preparations were dehydrated and embedded in resin and sectioned. Images were captured using a Biotwin Philips TECNAI G2
electron microscope. LEVs (4–5 µm) with intact membranes were observed to contain multiple organelles including lysosomes,
mitochondria and intermediate filaments but no nucleus. Images were captured at 2900 × magnification. Scale bar is 1 µm. (c) Human
LEVs were isolated from patient derived ALL xenografts using human CD19 immunocapture. Engrafted human ALL cells and LEVs were
harvested from the spleens of NSG mice by immuno-capture using a magnetic bead conjugated anti-human CD19 antibody. Eluates
were seeded onto CellTak coated ACLAR film and processed as in (a). The figure represents one of serial sections taken through the LEV
and neighbouring cell and shows the LEV to have an intact membrane, organelles and distinct cytoplasmic protrusions, but no nucleus.
(d) Representative serial sections through CD19 captured ALL cells and LEVs confirmed the size and absence of a nucleus. Serial
sections showed the LEV had an intact membrane, cytoplasmic protrusions, mitochondria and no nucleus and is ~4.2 µm in size.
Sections shown represent ~1 µm: Initial section shown is 200 nm thick followed by 11 sections at 80 nm.
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LEVs have an organised cytoskeleton, contain the
lysosome marker LAMP1 and are dynamically
active
Visualised following immobilisation onto CellTak
coated glass coverslips SD1, TOM1, NALM6 and
SupB15 cells produce large LEVs (<5 µm). Consistent
with the TEM findings, LEVs from BCP-ALL cell lines
were positive for the lysosome marker LAMP1
(Figure 3(a)). LEVs are distinct from parent cells and
demonstrate cytoskeletal structures including actin-
rich filopodia (filamentous actin labelled with Alexa
Fluor (555) Phalloidin; Figure 3(b)) and were anucleate
(DAPI-negative). Membrane blebs occur both in apop-
totic and migratory cells.[14] The development of
membrane blebs requires re-organisation of the cortical
cytoskeleton with recruitment of ezrin-radixin-myoesin
(ERM) family of proteins into the bleb and then stabi-
lisation by the polymerisation of actin.[15] We have
previously reported the presence of ERM proteins as
well as proteins involved in vesicle formation on the
plasma membrane of SD1 cells.[16] Investigating other
cytoskeletal components of LEVs showed that LEVs
from BCP-ALL cell lines SD1, TOM1, SupB15 and
NALM6 expressed filamentous actin, and the cytoske-
letal protein talin indicating the formation of focal
adhesions at the basal layer (Figure 4). ALL cell derived
LEVs also expressed the cytoskeletal adapter protein
vinculin (Figure 5(a)). Talin, vinculin and ERM pro-
teins cooperate with the linking of actin filaments to
the cytoskeleton, an activity regulated by the phospho-
lipid PtdIns(4,5)P2, suggesting that the formation of
LEVs is an active process.[17,18] This idea was sup-
ported by examining co-cultures of SD1GFP cells and
dsRED expressing bone marrow endothelial cells
(BMECdsRED); where GFP positive LEVs (LEVGFP)
were observed in the extracellular space (Figure 5(b)).
Large (<6 µm) SD1 LEVs exhibited independent,
dynamic shape-change and spontaneous movement
(Supplemental Video 1 hosted at ftp://ftp.picr.man.
ac.uk/ftpdata/).
LEVs are internalised by other cells
In the co-culture experiments described above, SD1GFP
cells were observed to make transient adhesions to




























Figure 3. Large LEVs have an organised cytoskeleton and contain the lysosome marker LAMP1. (a) LEVs contain polymerised,
filamentous actin and expressed LAMP1. SD1, TOM1, SupB15 and NALM6 ALL cell cultures immobilised on glass coverslips were
fixed and probed for the lysosomal protein LAMP1 (green; second row). Filamentous actin was labelled using Alexa Fluor 555
phalloidin (red: third row) and DAPI labelled the cell nucleus (blue – bottom row) whilst LEVs were negative for DAPI. Images were
captured using the Leica gSTED super resolution fluorescence microscope. Each cell preparation revealed parent cells and LEVs of
varying sizes. Gold arrows indicate LEVs and scale bars are 10 µm. (b) Region of interest as indicated by the gold box highlights the
SD1 cell-derived LEV which demonstrates distinct f-actin rich filopodia analogous to the parent cell.
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(Figure 6(a) for stills and best appreciated in
Supplemental Video 2). Neighbouring endothelial cells
appeared to engulf the released LEVs. To investigate this
process in vivo, NALM6GFP cells were engrafted intrave-
nously into NSG mice. Both parent NALM6GFP cells and
GFP+ LEVs were observed in samples obtained from bone
marrow flushes taken 19 days after engraftment, demon-
strating LEV production within the in vivo bone marrow
microenvironment (Figure 6(b)). Although we were able
to detect GFP+ LEVs in the extracellular space, we found
that GFP (and indeed the green fluorescence marker
PKH67, data not shown) was too weak to track LEV
uptake by murine BMSCs. Therefore, SupB15mCherry
cells were transplanted intrafemorally into NSG mice to
further investigate LEV production and uptake in vivo.
Bone marrow flushes were fixed and counterstained with
a fluorescent cell mask to allowmorphological distinction.
SupB15mCherry cells (not shown) andmBMSCs with inter-
nalised LEVmCherry were present along with LEVmCherry
negative mBMSCs (Figure 6(c)). We previously showed
that PKH26 labelled, isolated SD1 cell LEVs were inter-
nalised by murine BMSCs in vivo. A similar punctate,
peri-nuclear localisation was observed when LEVs alone
were administered.[7] These data demonstrate that ALL
cells produce LEVs within the bone marrow microenvir-
onment, contain parent cell cytoplasm and are interna-
lised by stromal cells both ex and in vivo.
Phenotypic alterations to recipient cells with
internalised LEVs
EVs released in vivo by aggressive tumour cells can
be internalised by neighbouring as well as remotely
located, less malignant cells and result in their trans-
formation to a more aggressive phenotype.[19] SDI
cells have a highly organised filamentous actin cytos-
keleton; show increased motility and invasion in
Boyden chamber assays and more readily infiltrate
across the blood–brain barrier in xenograft models.

















Figure 4. LEVs express talin at focal adhesion sites. SD1, TOM1, Sup15 and NALM6 cells alongside LEVs (gold arrows) were fixed as
described and probed for Talin. Images were captured using the Leica gSTED super resolution fluorescence microscope. LEVs were
found to be expressing talin at the basal layer, indicating focal adhesion formation on the CellTak (green: second row), contain
filamentous actin (red: third row) and were DAPI negative (blue: bottom row).
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aggressive phenotype compared with other BCP-ALL
cell lines used in this study. Less aggressive BCP-ALL
cell lines SupB15, REH and TOM1 and the normal
lymphoblastic cell line HRC57 were co-incubated for
24 h with pre-labelled SD1 LEVs. In all experiments,
a proportion of cells showed evidence of internalised
SD1 LEVs indicated by green fluorescence. Cells with
internalised LEVs displayed increased actin polymer-
isation, polarisation and distinct filamentous filopo-
dia (F-Actin, red) strikingly similar to the parent
SD1 cells, in contrast to those without internalised
LEVs (Figure 7).
Discussion
This paper describes the identification of LEVs of >2
μm in size in cell culture, in bone marrow flushes from
mice engrafted with ALL cells and in diagnostic bone
marrow aspirates from ALL patients. TEM showed
blebbing in ALL cells and thus within the current
parameters for classification of EVs, the larger LEVs
could fall into the class of apoptotic bodies (ABs).
However, TEM also showed that these large vesicles
contained intact subcellular organelles without nuclear
material or chromatin condensation and immunofluor-
escence microscopy revealed them to be DAPI nega-
tive. Furthermore, LEVs maintained independent
motility and exhibited dynamic shape change in vitro,
had an organised cytoskeleton and transformed the
phenotype of recipient cells. Time lapse microscopy
revealed LEVs being budded and released in an active
process by ALL cells which appear to retain viability
post vesicle release. LEVs adhered to CellTak, a cell
adhesive derived from mussels. These tight adhesions
could only be disrupted enzymatically by trypsinisa-
tion, suggesting expression of cell adhesion molecules,
as demonstrated in other studies.[4] Finally, LEVs
released by cell lines were strikingly similar in mor-
phology, size and content to those isolated from patient
derived ALL cells, adding confidence for their use as a
model of EV biology. These observations suggest that





















Figure 5. LEVs express the cytoskeletal adapter protein vinculin and are dynamically active. BCP-ALL cell lines release actin-rich LEVs
into the extracellular space. SD1, TOM1, SupB15 and NALM6 cultures were seeded onto coated coverslips and probed for vinculin
followed by Alexa Fluor 488 (green) conjugated anti-mouse antibody and counter-labelled for actin and nucleus. Images were
captured using a Zeiss Axiovert 200 M microscope fitted with a Zeiss Plan-Fluor 0.5 numerical aperture (NA) connected to an Andor
iXon DU888+ black and white camera. Illumination by UV light source was filtered using the SEDAT wheel filter set. The imaging
system and image composites were created using Metamorph software (Molecular Devices). Scale bar represents 10 µm. (b) Stills
from time-lapse microscopy demonstrate morphological change dsRED+ transduced BMECs were plated onto fibronectin coated
glass bottomed plates at ~80% confluence. GFP+ SD1 cells were added and images captured at 5 min intervals over 5 h at × 40
magnification. A low light system was used comprising a Zeiss microscope (as before) encased in an environmentally controlled
chamber maintained at 37°C and 5% CO2. The figure shows four sequential frames taken from the time lapse representing 15 min
in real time. A large GFP+ LEV can clearly be seen (black arrow) to change morphology over time. This is best appreciated from the
time-lapse video (Supplemental Video 1).
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extracellular vesicles, including a class of large EVs
containing intact organelles both in vitro and in vivo.
EVs have been identified in the peripheral blood,
[20] and diagnostic blood smears from leukaemic
patients.[21] Whilst we identified vesicles ranging
from 50 nm to 5.9 µm in size using a variety of
techniques, there is currently no single instrument
available to quantify all vesicles from any given sample.
Preparation of larger vesicles required careful preserva-
tion of morphology and an intact outer membrane, to
enable study of intra-vesicle content and to assess
composition. Applying cell biology techniques to
study vesicle biology has many challenges. The hetero-
geneity in size, different mechanisms of vesicle genera-
tion and lack of a clear single discriminatory marker
prevents the acquisition of truly quantitative data. The
methodology used in this study circumvented the need
for a pure population by applying analyses to all LEVs
collected from cell lines, primary cells and clinical
material.
The sequence of LEV exchange presented during
overnight time lapse experiments was sought across
multiple wells in several experiments. Specific co-cul-
ture interactions via vesicle exchange were often
obscured as cells were motile and the frequency of
this event is unclear. The presence of both GFP+ and
dsRED+ smaller vesicles in the extracellular space sug-
gests an abundance of heterogeneous EVs in the co-
culture supernatant derived from both cell types. The
microscopy experiments do not permit the visualisa-
tion of exchange of these smaller particles. Whilst we





































Figure 6. Transduced cells produce fluorescent LEVs in vitro and in vivo which are taken up by other cells. (a) Stills from time-lapse
microscopy demonstrate the uptake of a GFP+ LEV by dsRED BMECs. Co-cultures were established as previously described and this
figure represents four frames taken at 10-min intervals. Top line: Overlay of images acquired using bright field, GFP and RFP filters
(× 40 magnification). Middle line: expansion of indicated region of interest. Bottom line: images acquired using the RFP filter only.
Images begin following the release of the GFP+ LEV (black arrow) into the extracellular space. The dsRED+ bone marrow cell
appears to move towards the LEV which is internalised and shuttled within the recipient cell boundaries. Scale bar represents
10 µm. This sequence is best appreciated from the time-lapse video (Supplementary video 3). (b) Parent cells transfected to express
GFP produce GFP+ vesicles in vivo. GFP+ NALM6 cells were introduced into NSG mice by intravenous injection and allowed to
engraft. Bone marrow was flushed from the femurs 19 days later and plated onto CellTak coated glass bottomed plates. Images
were captured using bright field illumination and a GFP filter. The figure shows the overlay of the two channels and GFP only where
2 GFP+ LEVs can be seen (yellow arrow). This method facilitates identification of cell of origin within the in vivo microenvironment.
(c) LEVmCherry released in the murine bone marrow microenvironment are internalised by mBMSCs. SupB15 cells were transduced
to express mCherry and transplanted into the femur of NSG mice. Bone marrow flushes were obtained 44 days later, seeded onto
fibronectin and fixed. Parent ALL cells were transduced to express the fluorescent protein mCherry, produce and release mCherry+
LEVs in vivo. Cells were counterstained using Cell Mask green and images captured at × 160 magnification. Cell mask green labelled
adherent endogenous mBMSCs show internalised mCherry+ ALL LEVs within the cell membrane of two of the three BMSCs shown
here. These data also suggest that vesicle uptake is a selective process.
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BMSCs, suggesting an accumulation in recipient cell
endo-lysosomal compartments, the fate of internalised
LEVs also requires further investigation.
GFP+ or mCherry+ parent cells produced LEVs
whose origin could easily be identified; however, parent
cell identification in clinical samples remains a chal-
lenge. To demonstrate that LEVs were leukaemic spe-
cific, in our controlled experiments we used the B cell
surface antigen CD19 as a marker. However, the regen-
erating marrow has a population of normal BCP cells
that also express this antigen. Further work is required
to investigate if indeed LEVs can be distinguished
accurately from EVs released from normal B cells.
Currently the response to disease is measured by
repeated bone marrow aspirates to detect residual leu-
kaemic cells. As a single ALL cell produces a number of
LEVs and these are released into the peripheral circula-
tion, the accurate identification of such particles in
peripheral blood has the potential to become a highly
sensitive and specific biomarker of disease progression.
The concept that cells are capable of transferring orga-
nelles is not new; intercellular organelle transfer via nano-
tubules has been described [22,23] and the transfer of
healthy mitochondria to cells with defective or deleted
mitochondria can rescue aerobic respiration.[24] We pre-
viously reported the detection of LEVs in the peripheral
circulation of a patient-derived xenograft model.[7] Along
with other published data, this suggests that EVs have the
potential to travel to distal sites, influence the microenvir-
onment and establish sanctuary sites or a pre-metastatic
niche.[25,26] The internalisation of malignant EVs by
normal cells, as described here, provides a mechanism for
horizontal transfer, resulting in phenotypic transformation
of the recipient cell. This phenomenon has been reported
elsewhere in a murine mammary tumour model.[19] As
previously reported by us, exposure of bone marrow







































Figure 7. Uptake of SD1 LEVs by other suspension cells changes their actin phenotype. The BCP-ALL cell lines SupB15, REH and
TOM1 and the normal B lymphoblastic cell line HRC57 were co-incubated for 24 h with Dio C labelled SD1 LEVs (green). Cells were
washed and plated onto CellTak coated glass coverslips and labelled with Alexa Fluor Phalloidin to visualise polymerised actin (red)
and DAPI (blue). Cells with punctate, intracellular green fluorescence indicate internalised LEVs and correspond to increased actin
polarisation and presence of distinct filopodia. With each frame, cells are present within the field of view which have not
internalised LEVs and display significantly less polymerised actin, indicated by lower red fluorescence. Images were captured as
before at × 40, × 100 or × 160 magnification as indicated. Scale bar represents 20 µm.
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stromal cells to unselected LEVs resulted in a switch to
glycolysis.[7] Potentially, this may favour tumour survival,
particularly at times of oxidative or cytotoxic stress, and
give rise to disease recurrence.[8] LEVs may provide some
clues to unexplained conundrums in the therapeutic
responses in BCP-ALL. ALL is genetically heterogeneous
and composed of a number of subclones on a clonal back-
ground. Both clonal and subclonal genetic subgroups have
prognostic significance.[27,28] In general, within the clo-
nal cytogenetic subtypes, minor subclones present at diag-
nosis dominate at relapse,[29] but retain chemosensitivity
as second remissions are usually obtained.[28] This persis-
tent, partial chemosensitivity is difficult to explain within a
branching evolution model.[30] We have observed that
different ALL cell lines and patient samples produce a
varying number of LEVs, both in size and quantity.
Furthermore, not all cells in a sample produce vesicles. It
is possible then that certain “resistant” genetic subclones
may produce LEVs and protect more “sensitive” clones
either through horizontal transfer or by creating a chemo-
protective niche. It is also possible that CD19 positive LEVs
may act as decoy for CD19 directed therapy, leading to the
persistence of CD19 positive ALL cells in some patients.
[31,32]
This study presents observations supporting the idea
that EVs are major mediators of intercellular communi-
cation. LEVs contain cytoplasm from the parent cell as
indicated by GFP or mCherry expression, but the ques-
tion of whether their total cargo is precisely selected and
packaged into vesicles, rather than randomly, merits
further investigation. The abundance and direct relation-
ship to the tumour cell suggest that as better techniques
are established, EVs have the potential to become highly
sensitive and specific biomarkers. Irrespective of the
source of the EVs or mechanism of release, improvements
in our understanding of the mechanisms that regulate the
specificity of internalisation are also likely to lead to
advances in clinical and therapeutic applications.
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